Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Clinical benefits of evolocumab appear less than hoped – Authors’ reply

Our analysis1 of the association between LDL-cholesterol concentrations at 4 weeks and cardiovascular outcomes reported in FOURIER2 complemented the primary data from the randomised comparison between evolocumab and placebo. Unlike previous epidemiological studies and the selected studies cited by Simon B Dimmitt and colleagues, we analysed the association between the reduction of LDL-cholesterol concentrations to unprecedented low levels and clinical outcomes, adjusting for differences in baseline characteristics.